Rhythm Pharmaceuticals, Inc.
RYTM
Classificação em ações
#2958
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial... Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, including obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The firm, headquartered in Boston, Massachusetts, was established in 2008 and changed its name from Rhythm Metabolic, Inc. to Rhythm Pharmaceuticals, Inc. in October 2015.
Preço da ação
$90.58
Última sincronização: 2026-10-20
Valor de mercado
$6.24B
Variação (1 dia)
2.66%
Variação (1 ano)
-15.46%
País
US
Negociar Rhythm Pharmaceuticals, Inc. (RYTM)
Categoria
Healthcare
Receita da Rhythm Pharmaceuticals, Inc. (RYTM)
Receita em Jun 2026 TTM: $239.92M
De acordo com os últimos relatórios financeiros da Rhythm Pharmaceuticals, Inc., a receita atual da empresa (TTM) é $239.92M. Em 2023, a empresa obteve uma receita de $77.43M um aumento em relação a a receita do ano 2022, que foi de $23.64M. A receita é o valor total gerado pela venda de bens ou serviços. Ao contrário do lucro, nenhuma despesa é subtraída.
Histórico de receita da Rhythm Pharmaceuticals, Inc. de 2012 a 2026
Receita no final de cada ano
| Ano | Receita | Alterar |
|---|---|---|
| 2026 (TTM) | $239.92M | 84.37% |
| 2024 | $130.13M | 68.06% |
| 2023 | $77.43M | 227.56% |
| 2022 | $23.64M | 649.46% |
| 2021 | $3.15M | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
| 2015 | 0.00 | 0.00% |
| 2014 | 0.00 | 0.00% |
| 2013 | 0.00 | 0.00% |
| 2012 | 0.00 | 0.00% |
Receita de empresas similares ou concorrentes
| Empresa | Receita | Diferença de Receita | País |
|---|---|---|---|
| $12.62B | 5,161.92% |
US
|
|
| $2.23B | 828.65% |
US
|
|
| $15.74B | 6,462.38% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 2,409.73% |
NL
|
